OBJECTIVE: To characterize in vivo signatures of pathological diagnosis in a large cohort of patients with primary progressive aphasia (PPA) variants defined by current diagnostic classification. METHODS: Extensive clinical, cognitive, neuroimaging, and neuropathological data were collected from 69 patients with sporadic PPA, divided into 29 semantic (svPPA), 25 nonfluent (nfvPPA), 11 logopenic (lvPPA), and 4 mixed PPA. Patterns of gray matter (GM) and white matter (WM) atrophy at presentation were assessed and tested as predictors of pathological diagnosis using support vector machine (SVM) algorithms. RESULTS: A clinical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactive response DNA-binding protein (TDP) inclusions in 40.5%, FTLD-tau in 40.5%, and Alzheimer disease (AD) pathology in 19% of cases. Each variant was associated with 1 typical pathology; 24 of 29 (83%) svPPA showed FTLD-TDP type C, 22 of 25 (88%) nfvPPA showed FTLD-tau, and all 11 lvPPA had AD. Within FTLD-tau, 4R-tau pathology was commonly associated with nfvPPA, whereas Pick disease was observed in a minority of subjects across all variants except for lvPPA. Compared with pathologically typical cases, svPPA-tau showed significant extrapyramidal signs, greater executive impairment, and severe striatal and frontal GM and WM atrophy. nfvPPA-TDP patients lacked general motor symptoms or significant WM atrophy. Combining GM and WM volumes, SVM analysis showed 92.7% accuracy to distinguish FTLD-tau and FTLD-TDP pathologies across variants. INTERPRETATION: Each PPA clinical variant is associated with a typical and most frequent cognitive, neuroimaging, and neuropathological profile. Specific clinical and early anatomical features may suggest rare and atypical pathological diagnosis in vivo. Ann Neurol 2017;81:430-443.
OBJECTIVE: To characterize in vivo signatures of pathological diagnosis in a large cohort of patients with primary progressive aphasia (PPA) variants defined by current diagnostic classification. METHODS: Extensive clinical, cognitive, neuroimaging, and neuropathological data were collected from 69 patients with sporadic PPA, divided into 29 semantic (svPPA), 25 nonfluent (nfvPPA), 11 logopenic (lvPPA), and 4 mixed PPA. Patterns of gray matter (GM) and white matter (WM) atrophy at presentation were assessed and tested as predictors of pathological diagnosis using support vector machine (SVM) algorithms. RESULTS: A clinical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactive response DNA-binding protein (TDP) inclusions in 40.5%, FTLD-tau in 40.5%, and Alzheimer disease (AD) pathology in 19% of cases. Each variant was associated with 1 typical pathology; 24 of 29 (83%) svPPA showed FTLD-TDP type C, 22 of 25 (88%) nfvPPA showed FTLD-tau, and all 11 lvPPA had AD. Within FTLD-tau, 4R-tau pathology was commonly associated with nfvPPA, whereas Pick disease was observed in a minority of subjects across all variants except for lvPPA. Compared with pathologically typical cases, svPPA-tau showed significant extrapyramidal signs, greater executive impairment, and severe striatal and frontal GM and WM atrophy. nfvPPA-TDPpatients lacked general motor symptoms or significant WM atrophy. Combining GM and WM volumes, SVM analysis showed 92.7% accuracy to distinguish FTLD-tau and FTLD-TDP pathologies across variants. INTERPRETATION: Each PPA clinical variant is associated with a typical and most frequent cognitive, neuroimaging, and neuropathological profile. Specific clinical and early anatomical features may suggest rare and atypical pathological diagnosis in vivo. Ann Neurol 2017;81:430-443.
Authors: Keith A Josephs; Dennis W Dickson; Melissa E Murray; Matthew L Senjem; Joseph E Parisi; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell Journal: Brain Lang Date: 2013-03-28 Impact factor: 2.381
Authors: Stephen M Wilson; Jennifer M Ogar; Victor Laluz; Matthew Growdon; Jung Jang; Shenly Glenn; Bruce L Miller; Michael W Weiner; Maria Luisa Gorno-Tempini Journal: Neuroimage Date: 2009-06-06 Impact factor: 6.556
Authors: Jennifer M Harris; Claire Gall; Jennifer C Thompson; Anna M T Richardson; David Neary; Daniel du Plessis; Piyali Pal; David M A Mann; Julie S Snowden; Matthew Jones Journal: Neurology Date: 2013-10-18 Impact factor: 9.910
Authors: Yu Zhang; Norbert Schuff; Christopher Ching; Duygu Tosun; Wang Zhan; Marzieh Nezamzadeh; Howard J Rosen; Joel H Kramer; Maria Luisa Gorno-Tempini; Bruce L Miller; Michael W Weiner Journal: Int J Alzheimers Dis Date: 2011-06-27
Authors: Li Liu; Valerie Drouet; Jessica W Wu; Menno P Witter; Scott A Small; Catherine Clelland; Karen Duff Journal: PLoS One Date: 2012-02-01 Impact factor: 3.240
Authors: Camilla N Clark; Tammaryn Lashley; Colin J Mahoney; Jason D Warren; Tamas Revesz; Jonathan D Rohrer Journal: Cogn Behav Neurol Date: 2015-06 Impact factor: 1.600
Authors: Bob Olsson; Erik Portelius; Nicholas C Cullen; Åsa Sandelius; Henrik Zetterberg; Ulf Andreasson; Kina Höglund; David J Irwin; Murray Grossman; Daniel Weintraub; Alice Chen-Plotkin; David Wolk; Leo McCluskey; Lauren Elman; Leslie M Shaw; Jon B Toledo; Jennifer McBride; Pilar Hernandez-Con; Virginia M-Y Lee; John Q Trojanowski; Kaj Blennow Journal: JAMA Neurol Date: 2019-03-01 Impact factor: 18.302
Authors: Maya L Henry; H Isabel Hubbard; Stephanie M Grasso; Heather R Dial; Pélagie M Beeson; Bruce L Miller; Maria Luisa Gorno-Tempini Journal: J Speech Lang Hear Res Date: 2019-08-07 Impact factor: 2.297
Authors: Valentina Borghesani; Jared Narvid; Giovanni Battistella; Wendy Shwe; Christa Watson; Richard J Binney; Virginia Sturm; Zachary Miller; Maria Luisa Mandelli; Bruce Miller; Maria Luisa Gorno-Tempini Journal: Cortex Date: 2019-01-23 Impact factor: 4.027
Authors: Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger Journal: Lancet Neurol Date: 2017-06-13 Impact factor: 44.182
Authors: Elisa Canu; Federica Agosta; Giovanni Battistella; Edoardo G Spinelli; Jessica DeLeon; Ariane E Welch; Maria Luisa Mandelli; H Isabel Hubbard; Andrea Moro; Giuseppe Magnani; Stefano F Cappa; Bruce L Miller; Massimo Filippi; Maria Luisa Gorno-Tempini Journal: Neurology Date: 2020-01-10 Impact factor: 9.910